Patents Assigned to Oslo Universitetssykehus HF
-
Publication number: 20200018763Abstract: The present invention relates to methods for assessing binding agent specificity, in particular antibody specificity. The present invention thus provides a method of analysing a mixture of polypeptides comprising the steps of: (i) separating the polypeptides in the mixture into a plurality of fractions; (ii) contacting a first aliquot of two or more of the fractions with a plurality of different binding agents attached to one or more solid supports and detecting the binding of the polypeptides to the binding agents in each fraction; (iii) assessing the amino acid composition of the polypeptides in a second aliquot of said fractions by mass spectrometry; and (iv) correlating the binding results detected in step (ii) and the mass spectrometry results from step (iii) to assess the specificity of the binding agents for a polypeptide of interest.Type: ApplicationFiled: September 26, 2017Publication date: January 16, 2020Applicants: Oslo Universitetssykehus HF, Universitetet i OsloInventors: Fridtjof LUND-JOHANSEN, Krzsysztof SIKORSKI, Marit INNGJERDINGEN, Adi MEHTA
-
Publication number: 20190336529Abstract: The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated “?1A” frameshift mutation in human TGF?RII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and comprise an ?-chain domain and a ?-chain domain, each chain domain comprising three CDR sequences, wherein a) CDRs 1, 2 and 3 of the ?-chain domain have the sequences of SEQ ID NOs: 2, 3 and 4 respectively; and b) CDRs 1, 2 and 3 of the ?-chain domain have the sequences of SEQ ID NOs: 5, 6 and 7 respectively, and wherein one or more of said CDR sequences may optionally be modified by substitution, addition or deletion of 1 or 2 amino acids. Nucleic acid molecules encoding such TCRs are provided, as are soluble TCR molecules with these CDR sequences.Type: ApplicationFiled: May 9, 2017Publication date: November 7, 2019Applicant: Oslo Universitetssykehus HFInventors: Else Marit Inderberg, Gustav Gaudernack, Sèbastien Wälchli, Gunnar Kvalheim
-
Patent number: 10308980Abstract: The present invention relates to methods and biomarkers (e.g., gene expression biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer and in providing a prognosis to colorectal cancer patients.Type: GrantFiled: November 5, 2012Date of Patent: June 4, 2019Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: Ragnhild A. Lothe, Trude Holmeide Agesen, Anita Sveen, Guro Elisabeth Lind, Arild Nesbakken, Rolf Inge Skotheim
-
Publication number: 20180303691Abstract: A patient isolator includes a base and a cover which is arranged to seal with the base. The cover is formed from a rigid material and has two access ports on an end face. The two access ports are angled in a width direction relative to a plane which extends parallel to the width direction of the patient isolator. The two access ports are angled relative to each other. A method of isolating a patient from an environment is also disclosed.Type: ApplicationFiled: November 14, 2016Publication date: October 25, 2018Applicant: Oslo Universitetssykehus HFInventors: Fridtjof Heyerdahl, Knut Erik Hovda, Espen Rostrup Nakstad, Arne Broch Brantsaeter, Ronald Rolfsen
-
Patent number: 10023909Abstract: The present invention relates to methods and kits for the detection of 5-hydroxymethylcytosine (5hmC) and/or 5-methylcytosine (5meC). In some embodiments, the present invention relates to methods and kits for detection of 5hmC and/or 5meC in nucleic acid (e.g., DNA, RNA). In some embodiments, the present invention relates to detection of 5hmC in genomic DNA, e.g., mammalian genomic DNA.Type: GrantFiled: December 13, 2012Date of Patent: July 17, 2018Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: John Arne Dahl, Adam Brian Robertson, Arne Klungland, Linda Ellevog
-
Patent number: 9822417Abstract: The present invention relates to methods and biomarkers (e.g., gene expression biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer, providing a prognosis to colorectal cancer patients, and in companion diagnostics.Type: GrantFiled: January 9, 2013Date of Patent: November 21, 2017Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: Ragnhild A. Lothe, Anita Sveen, Trude Holmeide Agesen, Guro Elisabeth Lind, Arild Nesbakken, Rolf Inge Skotheim
-
Patent number: 9809859Abstract: The present invention relates to biomarkers for chemoradioresistant subtypes of cervical cancer. In particular the present invention relates to a method for predicting a predisposition to a chemoradioresistant cervical cancer in a subject, a method for diagnosing a chemoradioresistant cervical cancer in a subject, a method for predicting the likelihood of recurrence of cervical cancer in a cervical cancer patient under treatment, and a method for predicting the prognosis for a patient with a chemoradioresistant cervical cancer.Type: GrantFiled: March 20, 2015Date of Patent: November 7, 2017Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: Heidi Lyng, Malin Lando
-
Patent number: 9797016Abstract: The invention relates to methods and biomarkers (e.g., epigenetic biomarkers) for detection of bladder cancer in biological samples (e.g., tissue samples, urine samples, urine sediments). In some embodiments, methods and biomarkers of the present invention find use in discriminating between bladder cancer, prostate cancer and renal epithelial tumors.Type: GrantFiled: October 19, 2011Date of Patent: October 24, 2017Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: Guro Elisabeth Lind, Ragnhild A. Lothe, Rolf Inge Skotheim, Carmen Jeronimo, Vera L. Costa, Rui Henrique, Manuel R. Teixeira
-
Publication number: 20170296090Abstract: A method is described for determining biological tissue type based on a complex impedance spectra obtained from a probe with a conducting part adjacent a tissue region of interest, wherein the impedance spectra includes data from a number of frequencies. The method may include: obtaining, from the complex impedance spectra, a first data set representative of impedance modulus values, or equivalent admittance values, at one or more frequencies, obtaining, from the complex impedance spectra, a second data set representative of impedance phase angle values, or equivalent admittance values, at one or more different frequencies, applying a first discrimination criterion to the first data set, applying a second discrimination criterion to the second data set, and thereby determining if the tissue region of interest is a tissue type characterised by the discrimination criteria.Type: ApplicationFiled: October 12, 2015Publication date: October 19, 2017Applicant: OSLO UNIVERSITETSSYKEHUS HFInventors: Håvard KALVØY, Axel SAUTER, Audum STUBHAUG, Sverre GRIMENES, Ørjan G. MARTINSEN
-
Patent number: 9676829Abstract: The present invention discloses polypeptides with antibacterial properties and use said polypeptides and/or polynucleotides encoding said polypeptides in the preparation of medicament for the treatment of infectious diseases. The inventors also provide vectors encoding and adapted for expression of the polypeptides and polynucleotides of the invention. The vectors may be used in the preparation of a medicament for the treatment of bacterial infections. Further, the vector of the invention may be used to reduce the load of bacteria in food and/or feed.Type: GrantFiled: September 25, 2014Date of Patent: June 13, 2017Assignee: Oslo Universitetssykehus HFInventors: Ragnhild Weel-Sneve, James Alexander Booth, Magnar Bjørås, Knut Ivan Kristiansen
-
Patent number: 9677128Abstract: The present invention relates to methods and kits for the detection of 5-hydroxymethylcytosme (5hmC). In some embodiments, the present invention relates to methods and kits for detection of 5hmC in nucleic acid (e.g., DNA, RNA). In some embodiments, the present invention relates to detection of 5hmC in genomic DNA, e.g., mammalian genomic DNA.Type: GrantFiled: October 20, 2011Date of Patent: June 13, 2017Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: Adam Brian Robertson, John Arne Dahl, Arne Klungland
-
Patent number: 9506117Abstract: The present invention relates to methods and biomarkers for detection of cervical cancer in biological samples, and in particular to markers associated with hypoxia related to the cervical cancer.Type: GrantFiled: February 20, 2013Date of Patent: November 29, 2016Assignee: Oslo universitetssykehus HFInventors: Heidi Lyng, Cathinka Halle Julin
-
Publication number: 20160158472Abstract: There is provided a method of controlling a mechanical ventilator. The method may include the steps of receiving a measurement of transthoracic impedance of a patient obtained during chest compressions, determining a timing for a mechanical ventilator to provide a ventilation based on the measurement of transthoracic impedance, and sending a signal to control the mechanical ventilator based on the determined timing. There is also provided an apparatus for performing the method.Type: ApplicationFiled: July 21, 2014Publication date: June 9, 2016Applicant: Oslo Universitetssykehus HFInventor: Lars Wik
-
Publication number: 20160058895Abstract: Provided herein is technology relating to imaging agents for positron emission tomography (PET) and particularly, but not exclusively, to a gonadotropin-releasing hormone (GnRH) antagonist radiolabeled with positron emitting nuclides and to methods of visualizing GnRH receptors in the central nervous system by PET from administration of such compounds to warm-blooded animals for diagnostic purposes.Type: ApplicationFiled: April 18, 2014Publication date: March 3, 2016Applicant: Oslo Universitetssykehus HFInventors: Dag Erlend Olberg, Ira Hebold Haraldsen, Jo Klaveness
-
Patent number: 9217152Abstract: The present invention relates to the use of a dinQ-sRNA type I toxin-antitoxin systems for plasmid maintenance. An embodiment of the present invention relates to the use of the dinQ-sRNA type I toxin-antitoxin system for the manufacture of a plasmid selection system. In another embodiment of the present invention is the sRNA selected from the group consisting of agrA and agrB. Aspects of the present invention also relates to medical uses of the plasmid selection system.Type: GrantFiled: November 23, 2011Date of Patent: December 22, 2015Assignee: Oslo Universitetssykehus HFInventors: Ragnhild Weel-Sneve, James Booth, Magnar Bjoras, Knut Ivan Kristiansen
-
Publication number: 20140296096Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to polypeptides found in extracellular microvesicles as diagnostic and screening markers, and clinical targets for cancer (e.g., prostate cancer).Type: ApplicationFiled: March 27, 2014Publication date: October 2, 2014Applicant: Oslo universitetssykehus HFInventors: Alicia Llorente, Tore Skotland, Kirsten Sandvig
-
Publication number: 20140248292Abstract: The present invention relates to compositions and methods for treating cancer. In particular, the present invention relates to EpCAM-targeted immunotoxins and uses thereof in treating peritoneal cancers expressing EpCAM (e.g., colorectal, ovarian, and pancreatic cancer).Type: ApplicationFiled: March 4, 2014Publication date: September 4, 2014Applicant: Oslo universitetssykehus HFInventors: Kjersti Flatmark, Yvonne Andersson, Oystein Fodstad
-
Patent number: 8718747Abstract: The invention provides a method, an image analysis software product, and a system for medical imaging analysis for estimating contrast agent extravasation in contrast agent based perfusion imaging such as MRI dynamic contrast enhanced (DCE) imaging, and in particular correction, compensation, or visualization of extravascular leakage of contrast agent in tumors. According to the invention, the effect of extravasation is directly manifested in the tail part of an observed, apparent residue function, R?(t), obtained directly by de-convoluting the expression C(t)=R?(t)Cp?(t) with the arterial input function (AIF). A leakage rate or extravasation constant is determined directly from the tail part of the determined apparent residue function.Type: GrantFiled: April 18, 2011Date of Patent: May 6, 2014Assignee: Oslo Universitetssykehus HFInventors: Atle Bjørnerud, Kyrre Eeg Emblem
-
Publication number: 20140031257Abstract: The present invention relates to methods and biomarkers (e.g., epigenetic biomarkers) for detection of gastrointestinal cancers (e.g., colorectal cancer, gastric cancer, pancreatic cancer, liver cancer, cancer of the gall bladder and/or bile ducts (e.g., cholangiocarcinoma)) in biological samples (e.g., tissue samples, stool samples, blood samples, plasma samples, cell samples, gall samples, bile samples, serum samples).Type: ApplicationFiled: March 8, 2012Publication date: January 30, 2014Applicant: OSLO UNIVERSITETSSYKEHUS HFInventors: Ragnhild A. Lothe, Guro E. Lind, Deeqa Ahmed, Kim Andresen, Rolf I. Skotheim
-
Patent number: 8626279Abstract: The present invention relates to methods for predicting the risk for ventricular arrhythmias in a subject who has previously suffered a myocardial infarction (MI) or suffers from a primary cardiomyopathy, said method comprising measuring the myocardial mechanical dispersion in said subject and estimating the risk for ventricular arrhythmias based on said measurements. Similar the invention relates to a method for evaluating whether a subject is a candidate for implantable cardioverter-defibrillator (ICD) therapy.Type: GrantFiled: February 22, 2011Date of Patent: January 7, 2014Assignee: Oslo Universitetssykehus HFInventors: Thor Edvardsen, Kristina Haugaa, Jan Amlie